Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, W.
Right arrow Articles by Damber, J.-E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, W.
Right arrow Articles by Damber, J.-E.
Clinical Cancer Research Vol. 11, 3250-3256, May 1, 2005
© 2005 American Association for Cancer Research

Imaging, Diagnosis, Prognosis

Cyclooxygenase-2 Expression Correlates with Local Chronic Inflammation and Tumor Neovascularization in Human Prostate Cancer

Wanzhong Wang1, Anders Bergh2 and Jan-Erik Damber1

Authors' Affiliations: 1 Department of Urology, Sahlgrenska University Hospital, Göteborg University, Göteborg, Sweden and 2 Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden

Requests for reprints: Jan-Erik Damber, Department of Urology, Sahlgrenska University Hospital, SE-413 45 Göteborg, Sweden. Phone: 46-31-342-3977; Fax: 46-31-416347; E-mail: jan-erik.damber{at}urology.gu.se.


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
Purpose: Chronic inflammation is linked to the development of cancer in several organs, including the prostate. Up-regulated cyclooxygenase-2 (COX-2) may play a role in influencing cell proliferation, differentiation, apoptosis, or angiogenesis. This study aimed to derive data from human prostate cancer to investigate whether chronic inflammation and angiogenesis were correlated with the expression of COX-2.

Experimental Design: In this study, we did double-immunohistochemical analysis of a set of 43 human prostate cancer for COX-2 expression and the correlation with T-lymphocyte and macrophage densities and CD31-marked microvessel density (MVD) in situ.

Results: COX-2 positive staining was detected in 40/43 cancer samples with the very heterogeneous expression. Elevated COX-2 expression was associated with high Gleason score (P = 0.002). Foci of chronic inflammation were found in all 43 samples. COX-2–positive areas were noted with high T-lymphocyte and macrophage densities than COX-2–negative tumor areas (P < 0.0001 and P = 0.001, respectively). MVD were also found higher in COX-2–positive areas than in COX-2–negative tumor areas (P = 0.001).

Conclusions: This study shows a novel relationship between COX-2 expression and the local chronic inflammation within prostate cancer and the increased angiogenesis. It is likely that the proinflmmatory cytokines, released by T-lymphocytes and macrophages, up-regulate COX-2 in adjacent tumor cells and stimulate the angiogenesis in stromal tissues. These findings suggest that COX-2 may be an effective therapeutic target in prostate cancer treatment.

Key Words: COX-2 • prostate cancer • inflammation

Chronic inflammation of long-standing duration has been linked to the development of tumors in several organs, including the prostate (1). In fact, several studies have suggested that ~15% of malignancies worldwide are attributed to inflammation (2, 3). The inflammatory microenvironment, which is characterized by accumulation of different types of inflammatory cells in the tissue stroma and epithelium, may support the development of malignancy by secreting various proteases, mitogenic, antiapoptotic, and angiogenic factors (2). Elevated levels of proinflammatory cytokines may induce a network of regulatory factors that influence cell survival, growth, differentiation, and movement of both tumor and stromal cells (3) as well as induction of cyclooxygenase-2 (COX-2) expression.

COX is the enzyme responsible for the production of prostaglandins from arachidonic acid. Accumulating evidence shows that COX-2, through production of prostaglandins, may play a key role in tumorigenesis of a variety of human malignancies by stimulating cell proliferation (4, 5), inhibiting epithelial differentiation (6), enhancing cell invasiveness and tumor metastasis (7–9), inhibiting apoptosis (10), mediating immune suppression, and increasing the production of mutagens (11). COX-2 also contributes to angiogenesis (12–14), a crucial process for tumor growth and metastasis. Furthermore, epidemiologic studies have documented that the use of nonsteroidal anti-inflammatory drugs reduces colon cancer risk by 40–50% (15). The mechanism underlying the chemopreventive effects of nonsteroidal anti-inflammatory drugs may be related to their ability to inhibit COX-2.

Several lines of evidence suggest a connection between inflammation and prostate cancer. Polymorphisms and mutations in genes regulating the inflammatory process have been linked to prostate cancer risk (16). Prostatitis is apparently a risk factor for prostate cancer (16, 17) and the risk of biochemical relapse following radical prostatectomy is increased in patients with high-grade inflammation surrounding malignant glands (18); however, the mechanism by which inflammation influences the development and behavior of prostate cancer is unclear.

In a previous study, we have shown that COX-2 is locally up-regulated in prostate luminal epithelial cells in benign prostate hyperplasia if T-lymphocytes and macrophages are present. Such COX-2 positive epithelial cells had higher levels of Bcl-2 immunostaining and higher proliferation when compared with COX-2 negative cells (19). In this study, we analyzed if COX-2 expression in human prostate cancer is associated with local inflammation using double staining immunohistochemistry technique. In addition, we assessed the relationship between COX-2 and Gleason score of prostate cancer and reported a new finding of a relationship between COX-2 expression and microvessel density (MVD) in prostate cancer.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Tissue samples. The material comprised 43 specimens of prostate cancer. All of the tissues had been fixed in formalin and processed routinely through graded alcohols to paraffin blocks. Tissues were obtained from patients with prostate cancer undergoing prostatectomy at the Department of Urology, Sahlgrenska University Hospital, Göteborg University, Sweden (n = 28) and at the Department of Urology, Shandong Provincial Hospital, China (n = 15). Histologic diagnosis of prostate cancer was based on H&E-stained sections. The Gleason system was used for histologic grading. A primary and secondary Gleason grade (1-5) was determined for each tumor, and the combined score (Gleason sum) was then calculated. To obtain sufficient quantities for statistical analysis, the tumors were grouped in two categories: low grade if the Gleason score was 7 or less (n = 28), and high grade if the Gleason score was >7 (n = 15).

Antibodies. COX-2 affinity–purified polyclonal antibody was obtained from Cayman Chemical Co. (Ann Arbor, MI). CD3 (Ready to Use), CD31 (working dilution 1:25), and CD68 (Ready to Use) were purchased commercially from NeoMarkers Co. (Fremont, CA).

Immunohistochemical staining. COX-2 immunohistochemical staining was done using the ABC kit (Vector Laboratories, Inc., Burlingame, CA). Briefly (19), deparaffinized sections (4 µm) were rinsed with methyl alcohol-hydrogen peroxide and then microwaved in citrate buffer (pH 6.0) to induce epitope retrieval. Diluted COX-2 primary antibody (1:100) was incubated on slides at +4°C overnight and then incubated with biotinylated secondary antibody at room temperature. For localization, avidin-biotin complex was applied at room temperature for 30 minutes followed by 3,3'-diaminobenzidine tetrahydrochloride as the chromagen. Slides were counterstained with Mayer hematoxylin.

The specificity of the antibody was evaluated by preadsorption of the COX-2 antibody with a COX-2–specific blocking peptide (Cayman) before the staining procedure. The rabbit polyclonal affinity-purified immunoglobulin G was raised against a peptide corresponding to amino acids 584 to 598 of murine COX-2. According to information given by the manufacturers, it cross-reacts with the human COX-2 and has negative reaction with COX-1. A COX-2–specific blocking peptide, which derived from the human COX-2 cDNA sequence, was used in conjunction with COX-2 polyclonal antibody (Cayman) to block antibody/protein complex formation during immunochemical analysis for COX-2. COX-2 blocking peptide was mixed with the COX-2 antibody in a 1:1 (w/w) ratio in a microfuge tube with the dilution of 1:100 and incubated for 1 hour at room temperature before application of the antibody to the slide. Then the manual immunohistochemistry was done as described above. In all cases, the immunoreactivity of COX-2 was completely blocked by COX-2 blocking peptide (Fig. 1) in line with other studies (19, 20).



View larger version (75K):
[in this window]
[in a new window]
  		Fig. 1. COX-2 immunohistochemical staining in prostate cancer. Note the heterogeneous immunoreactivity in the cancer tissues (magnification: A, x100; B, x200; bottom-left insets, original x 400). Top-right insets, immunostaining was completely blocked by the COX-2 blocking peptide (original x 200).

 
Double immunohistochemical staining. To evaluate accurately the expression of COX-2 and the presence of related reagents on the same tissue section in situ, double immunohistochemical staining was done with the following combination of antibodies: COX-2/CD3 and COX-2/CD68 were used to mark the types of chronic inflammatory cells within prostate; COX-2/CD31 was designed to label the microvessels in condition of COX-2 staining (21). DAKO EnVision Doublestain System (Carpinteria, CA) was used in this procedure. Briefly (19), serially consecutive sections were treated for epitope retrieval as described above. After being incubated with peroxidase block for 5 minutes at room temperature, the slides were exposed to COX-2 primary antibody (1:100) and incubated at +4°C overnight. The slides were then incubated with horseradish peroxidase–labeled polymer for 30 minutes at room temperature. COX-2 immunostaining was labeled by applying 3,3'-diaminobenzidine tetrahydrochloride for 1 to 5 minutes. Next, doublestain block was added to the slides, and the slides were incubated for 3 minutes. Then, the slides were incubated with the second primary antibodies for 30 minutes at room temperature followed by an application of alkaline phosphatase–labeled polymer for another 30 minutes. The second substrate-chromagen solution, Fast Red, was incubated on the slides for 1 to 5 minutes. Slides were counterstained with Mayer hematoxylin and coverslipped with DAKO Glycergel.

Cyclooxygenase-2 immunohistochemical expression scores. COX-2 positive staining was identified by the presence of marked diffuse brown (3,3'-diaminobenzidine tetrahydrochloride) cytoplasm or perinuclear staining in prostate cancer cells. Quantitation of COX-2 immunohistochemical expression score was done using 10 to 20 ocular measuring fields chosen randomly under a microscope set at x200 magnification. Each slide was scored independently and the results were summed. The immunostaining results were scored separately according to the criteria of Krajewska et al. (22). The extension of positive tumor cells was graded as follows: 0, none; 1, positive staining cells <1/3; 2, 1/3-2/3; 3, >2/3. The immunostaining intensity was rated as follows: 0, none; 1, weak staining; 2, moderate; 3, strong. A score was calculated in which the extension was multiplied by the intensity rating (score range from 0 to 9) for each case. The COX-2 immunohistochemical expression scores were categorized as follows: grade 1, negative (0); grade 2, low (1-3); grade 3, intermediate (4-6); and grade 4, high (>7).

Evaluation of double immunohistochemical staining. The two antigens staining in double immunohistochemical staining slides were identified by colors: the first antigen, COX-2, was stained brown (3,3'-diaminobenzidine tetrahydrochloride) and the second one was stained red (Fast Red). For example, apart from the brown immunostaining of COX-2 on prostate cancer cells in COX-2/CD31 double immunohistochemical staining slides, the endothelial cells were labeled with cytoplasm red staining. Any single endothelial cells or cluster of endothelial cells that was labeled with CD31 was regarded as a single microvessel (23). The quantification of inflammatory cells or microvessel densities was done by counting 20 to 40 randomly selected microscopic fields of prostate cancer at x400 magnification [high power fields (HPF)] for each slide on COX-2/CD3, COX-2/CD68, or COX-2/CD31 double immunohistochemical staining sections and the values of the second antigen staining were regarded as inflammatory cell density or MVD.

Statistics. Statistical analysis was carried using SPSS 12.0 for Windows software. The COX-2 expression immunohistochemical score and the relationship with Gleason score, inflammatory cell density, and MVD were analyzed with Mann-Whitney U test. The strength of association between the COX-2 immunohistochemical score and inflammatory cell density or MVD was assessed using the Spearman rank correlation coefficient test.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
The heterogeneous cyclooxygenase-2 immunoreactivity. COX-2 immunohistochemical expression was observed showing a predominant cytoplasmic or perinuclear staining in prostate cancer cells. Adjacent stromal cells stained weakly positive. No COX-2 immunostaining was done in the vascular endothelium. COX-2 heterogeneous staining, both in the percentage of tumor cells stained and in staining intensity, was observed in most cases. Intense positive-staining cells, even the scattered positive tumor cells, were not always present (Fig. 1; refs. 24, 25). Accumulation of COX-2–positive tumor cells was particularly conspicuous in areas with chronic inflammation. In the surrounding nonmalignant prostatic glands, scattered COX-2–staining epithelium was detected in atrophic glands that were infiltrated by inflammatory cells (19).

Relationship between cyclooxygenase-2 expression and Gleason score. Overall, COX-2–positive tumor cells were detected in 40 of 43 cancer samples. The quantitative immunostaining data showed that majority of them (28 of 43, 65.1%) had the weak COX-2 immunostaining (COX-2 immunohistochemical score ≤ 3); 12 of 43 samples (27.9%) had the intermediate or strong COX-2 expression (COX-2 immunohistochemical score > 3). There was a significant association between elevated COX-2 expression and Gleason score. Quantification showed that the mean COX-2 immunohistochemical score was 1.13 (± 0.85) in low Gleason score specimens (n = 28). In contrast, the high Gleason score cases (n = 15) had increased COX-2 staining score (2.41 ± 1.95; P = 0.002).

Focal chronic inflammation and the up-regulation of cyclooxygenase-2 in adjacent tumor cells. Foci of chronic inflammation, with accumulation of T-lymphocytes and macrophages, were detected in all 43 prostate cancer samples (Fig. 2). Quantification of double labeling of COX-2/CD3 showed that the T-lymphocyte density was heterogeneous from 0 to 38 / HPF with a mean density of 7.95 (± 5.78) / HPF. No significant difference in T-lymphocyte density was found between the low and high Gleason score groups (P = 0.175). A higher T-lymphocyte density was found in COX-2–positive (9.51 ± 6.56 / HPF) than in COX-2–negative tumor fields (5.57 ± 3.15 / HPF; P < 0.0001). Further analysis showed that T-lymphocyte density was related to COX-2 expression in both the low and high Gleason score groups (P = 0.001 and 0.028, respectively). There was a significant positive correlation between T-lymphocyte density and COX-2 expression score (Spearman rank correlation coefficient test, {rho} = 0.390, P < 0.0001; Fig. 3A; Tables 1 and 2).



View larger version (144K):
[in this window]
[in a new window]
  		Fig. 2. COX-2 expression in relation to chronic inflammation (x200; insets, original x 400). A, tumor cells in a Gleason score 5 patient only showing strong COX-2 immunostaining (brown, arrowhead) in the area with intense T-lymphocyte (red, arrow) infiltration. B, cancer cells showing intense expression of COX-2 (brown, arrowheads) in a Gleason score 9 patient. T-lymphocytes (red, arrow) are also present. C, tumor cells in a Gleason score 5 tumor showing focal COX-2 positive immunostaining (brown, arrowhead) in the area with macrophage (red, arrow) infiltration. D, tumor cells in a Gleason score 8 tumor with intense macrophage infiltration (red, arrow) showing strong COX-2 expression (brown, arrowheads).

 


View larger version (45K):
[in this window]
[in a new window]
  		Fig. 3. T-lymphocyte (A) and macrophage (B) density in relation to COX-2 immunohistochemical score in prostate cancer with various Gleason scores. Columns, mean; bars, SE (*, P ≤ 0.0001; **, P = 0.01; ***, P = 0.002).

 

View this table:
[in this window]
[in a new window]
  		Table 1. Inflammatory cell densities in relation to Gleason score and COX-2 expression in prostate cancer tissue

 

View this table:
[in this window]
[in a new window]
  		Table 2. Inflammatory cell density in relation to COX-2 expression in prostate cancer tissue of various Gleason scores

 
CD68 immunostaining showed that the macrophage density varied widely within prostate cancer tissues. The mean macrophage density was 3.64 (± 2.59) / HPF with a median of 2.95 / HPF and ranging from 0 to 17 / HPF. Macrophage density was not significantly different between the low and high Gleason score specimens (P = 0.118). However, the macrophage density was higher in COX-2–positive tumor fields (2.22 ± 1.35 / HPF) than in COX-2–negative fields (3.89 ± 2.73 / HPF, P = 0.001). A significant positive correlation was shown between COX-2 immunohistochemical expression score and macrophage density (Spearman rank correlation coefficient test, {rho} = 0.358, P < 0.0001). Interestingly, COX-2 expression was significantly related to macrophage density in low Gleason score specimens ({rho} = 0.492, P < 0.0001) but not in high Gleason score specimens ({rho} = 0.175, P = 0.315; Fig. 3B; Tables 1 and 2).

Cyclooxygenase-2 expression and microvessel density. The spatial relationship between COX-2–expressing cancer cells and CD31-marked microvessels was investigated using COX-2/CD31 double immunohistochemical staining. COX-2 protein expression was not detected in endothelial cells (Fig. 4). In all cases, the mean CD31-labeled MVD was 6.37 / HPF with a median MVD value of 5.73 (0-18) / HPF. MVD was significantly increased in high Gleason score cases (8.02 ± 2.95 / HPF) compared with low Gleason score cancer specimens (5.30 ± 1.52 / HPF, P < 0.0001). A significant difference in MVD was also noted between COX-2–negative (5.50 ± 2.10 / HPF) and COX-2–positive staining areas (7.06 ± 2.71 / HPF; P = 0.001). Spearman rank correlation coefficient test showed a significant correlation between MVD and COX-2 expression score ({rho} = 0.434, P < 0.0001; Fig. 5; Table 3).



View larger version (146K):
[in this window]
[in a new window]
  		Fig. 4. COX-2 expression and microvessel distribution in human prostate (x200; insets, original x 400). A, focal COX-2–positive staining prostate epithelial cells (brown, arrowheads) in atrophic prostate glands and the CD31-marked blood vessels (red, arrows) in surrounding nonmalignant prostate tissues. B, a Gleason score 6 tumor with COX-2 negative immunostaining and sparse CD31-marked blood vessels (red, arrows). C, a Gleason score 5 tumor with COX-2 positive immunostaining (brown, arrowheads). Arrows, CD31-marked blood vessels. D, a Gleason score 9 tumor with strong COX-2 immunostaining (brown, arrowhead) and dense blood vessels (red, arrow).

 


View larger version (33K):
[in this window]
[in a new window]
  		Fig. 5. MVD in relation to COX-2 immunohistochemical score in prostate cancer with various Gleason scores. Columns, mean; bars, SE (*, P < 0.05; **, P = 0.001).

 

View this table:
[in this window]
[in a new window]
  		Table 3. MVD in relation to Gleason score and COX-2 expression in prostate cancer tissues

 

   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
In this study, we show, using double immunohistochemical techniques, that prostate tumor cells adjacent to areas with chronic inflammation up-regulate COX-2. We also show that vascular density is higher in inflamed than in noninflamed tumor areas, and COX-2 expression is increased in high Gleason score cancer specimens. Our finding of an increased number of COX-2 positive cells in high-grade cancer is generally in line with previous observations (25–27). These studies conclude that there is an up-regulation of COX-2 in prostate cancer and in some COX-2 staining is related to tumor differentiation (28, 29). A more recent study, however, showed that COX-2 protein expression is not consistently elevated in prostate cancer and does not correlate with established clinical-pathologic risk factors such as Gleason score and pathologic stage (24). In addition, the study noted that COX-2 protein was consistently observed in areas of postinflammatory atrophy, one kind of lesion that has been implicated in prostatic carcinogenesis. To date, however, there are few quantitative analyses of COX-2 expression in relation to Gleason score. In the present study, the COX-2 positive rate (93%) is higher than in any other report. This discrepancy can probably be explained by the fact that there is a very heterogeneous expression of COX-2 in prostate cancer tissues. A detailed quantitative analysis, based on the information of each microscopic field instead of the whole slide of each sample, may be the best way to interpret such heterogeneous findings.

Our data suggest that COX-2 expression is up-regulated focally in tumor areas with chronic inflammation, an observation that has heretofore not been noted. This observation is in line with our previous finding in benign prostate hyperplasia that COX-2 expression in benign prostate epithelium is correlated with local chronic inflammation, especially with accumulation of T-lymphocytes and macrophages (19). A significant correlation was found between COX-2 expression in tumor cells, especially in the low Gleason score specimens, and inflammatory cell density, both of T-lymphocytes and macrophages. The mechanism behind the association between inflammation and COX-2 expression in epithelial cells is not fully established. Several studies, however, have shown that COX-2 is up-regulated by factors such as interleukins 1, 4, 6, and 13, vascular endothelial growth factor, and tumor necrosis factor {alpha} (30–33), which are released by macrophages or activated T-lymphocytes (34). Moreover, in cell coculture experiments, COX-2 is induced by the presence of inflammatory cells (35). In normal prostate cells and prostate cancer cells, COX-2 protein levels are increased after tumor necrosis factor-{alpha} stimulation in vitro (36, 37). These observations suggest that the proinflammatroy cytokines released by T-lymphocytes and macrophages may contribute to the up-regulation of COX-2 in adjacent tumor cells.

This study provides the first evidence of a direct link between COX-2 and angiogenesis in prostate cancer tissue. This correlation is consistent with observations in colon, breast, liver, and endometrial tumors (38–41). Angiogenesis in prostate cancer is regulated by a variety of stimulatory factors like vascular endothelial growth factor, interleukin 8, tumor necrosis factor {alpha}, and inhibitors such as pigment epithelium–derived factor and thrombospondin 1 (42). These regulators are produced by tumor epithelial cells, stroma cells, and inflammatory cells (42). Interestingly, some of these factors could also induce COX-2 expression in vitro (30, 32, 37). The contribution of inflammatory mediators to the angiogenesis of tumors and their growth is becoming evident (25). COX-2 may stimulate angiogenesis through the production of angiogenic factors such as prostaglandins and vascular endothelial growth factor (5, 14). Angiogenesis of the tumor tissues can be suppressed by the COX-2 inhibitor celecoxib (25). Collectively, these observations suggest that the correlation between COX-2 expression and angiogenesis could be related either to the secretion of angiogenic prostaglandins from COX-2–expressing tumor cells or to the possibility that inflammatory cells secrete factors that directly stimulate angiogenesis.

The observation that up-regulation of COX-2 in nonmalignant prostate epithelial cells (19) and prostate cancer cells is related to chronic inflammation and increase of tumor angiogenesis may have chemopreventive and therapeutic implications in prostate cancer. It might be suggested that COX-2 inhibitors, through inhibition of the proinflammatroy cytokines, inhibit the procession of precancerous lesions and the angiogenesis of tumors. In fact, studies in experimental models have shown that COX-2 inhibitors suppress the growth and angiogenesis of prostate cancer (7, 14, 37, 43, 44). In addition, several studies have already recognized that nonsteroidal anti-inflammatory drugs have a dramatic antitumor effect in prostate cancer both in vivo (45) and in vitro (10). Additionally, a cohort study (46) and a case-control study (47) report strong inverse associations between nonsteroidal anti-inflammatory drug intake and risk of prostate cancer.


   Footnotes
 
Grant support: The Swedish Cancer Society, The Gunnar Nilssons Foundation, The Maud and Birger Gustavssons Foundation, and The Sahlgrenska University Hospital.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 11/24/04; revised 1/24/05; accepted 2/ 2/05.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Weitzman SA, Gordon LI. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 1990;76:655–63.[Abstract/Free Full Text]
  2. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001;85:473–83.[CrossRef][Medline]
  3. Coussens LM, Werb Z. Inflammatory cells and cancer: think different! J Exp Med 2001;193:F23–6.
  4. Lee DW, Sung MW, Park SW, et al. Increased cyclooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs. Anticancer Res 2002;22:2089–96.[Medline]
  5. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589–94.[Medline]
  6. McGinty A, Chang YW, Sorokin A, Bokemeyer D, Dunn MJ. Cyclooxygenase-2 expression inhibits trophic withdrawal apoptosis in nerve growth factor-differentiated PC12 cells. J Biol Chem 2000;275:12095–101.[Abstract/Free Full Text]
  7. Nithipatikom K, Isbell MA, Lindholm PF, et al. Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion. Clin Exp Metastasis 2002;19:593–601.[CrossRef][Medline]
  8. Murata H, Kawano S, Tsuji S, et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999;94:451–5.[CrossRef][Medline]
  9. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336–40.[Abstract/Free Full Text]
  10. Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998;58:4245–9.[Abstract/Free Full Text]
  11. Pruthi RS, Derksen E, Gaston K. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J Urol 2003;169:2352–9.[CrossRef][Medline]
  12. Chu J, Lloyd FL, Trifan OC, Knapp B, Rizzo MT. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther 2003;2:1–7.[Abstract/Free Full Text]
  13. Leung WK, To KF, Go MY, et al. Cyclooxygenase-2 up-regulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma. Int J Oncol 2003;23:1317–22.[Medline]
  14. Fujita H, Koshida K, Keller ET, et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 2002;53:232–40.[CrossRef][Medline]
  15. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252–66.[Abstract/Free Full Text]
  16. Nelson WG, DeWeese TL, DeMarzo AM. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 2002;21:3–16.[CrossRef][Medline]
  17. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002;60:78–83.
  18. Irani J, Goujon JM, Ragni E, et al. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group. Urology 1999;54:467–72.[CrossRef][Medline]
  19. Wang W, Bergh A, Damber JE. Chronic Inflammation in Benign Prostate Hyperplasia is Associated with Focal Up-regulation of Cyclooxygenase-2, Bcl-2, and Cell Proliferation in the Glandular Epithelium. Prostate 2004;61:60–72.[CrossRef][Medline]
  20. Saukkonen K, Nieminen O, van Rees B, et al. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res 2001;7:1923–31.[Abstract/Free Full Text]
  21. Engel CJ, Bennett ST, Chambers AF, et al. Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging. Am J Surg Pathol 1996;20:1260–5.[CrossRef][Medline]
  22. Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567–76.[Abstract]
  23. Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000;6:4064–8.[Abstract/Free Full Text]
  24. Zha S, Gage WR, Sauvageot J, et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001;61:8617–23.[Abstract/Free Full Text]
  25. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306–11.[Abstract/Free Full Text]
  26. Kirschenbaum A, Klausner AP, Lee R, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 2000;56:671–6.[CrossRef][Medline]
  27. Yoshimura R, Sano H, Masuda C, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000;89:589–96.[CrossRef][Medline]
  28. Madaan S, Abel PD, Chaudhary KS, et al. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int 2000;86:736–41.[CrossRef][Medline]
  29. Shappell SB, Manning S, Boeglin WE, et al. Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia 2001;3:287–303.[CrossRef][Medline]
  30. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539–45.
  31. Maloney CG, Kutchera WA, Albertine KH, et al. Inflammatory agonists induce cyclooxygenase type 2 expression by human neutrophils. J Immunol 1998;160:1402–10.[Abstract/Free Full Text]
  32. Berg J, Stocher M, Bogner S, et al. Inducible cyclooxygenase-2 gene expression in the human thyroid epithelial cell line Nthy-ori3-1. Inflamm Res 2000;49:139–43.[CrossRef][Medline]
  33. Luo JC, Shin VY, Yang YH, et al. Tumor necrosis factor-{alpha} stimulates gastric epithelial cell proliferation. Am J Physiol Gastrointest Liver Physiol 2005;288:G32–8.[Abstract/Free Full Text]
  34. Baron JA, Sandler RS. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 2000;51:511–23.[CrossRef][Medline]
  35. Yucel-Lindberg T, Brunius G, Wondimu B, Anduren I, Modeer T. Enhanced cyclooxygenase-2 mRNA expression in human gingival fibroblasts induced by cell contact with human lymphocytes. Eur J Oral Sci 2001;109:187–92.[Medline]
  36. Konig JE, Senge T, Allhoff EP, Konig W. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 2004;58:121–9.[CrossRef][Medline]
  37. Subbarayan V, Sabichi AL, Llansa N, Lippman SM, Menter DG. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-{alpha} in normal and malignant prostate cells. Cancer Res 2001;61:2720–6.[Abstract/Free Full Text]
  38. Chapple KS, Scott N, Guillou PJ, Coletta PL, Hull MA. Interstitial cell cyclooxygenase-2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas. J Pathol 2002;198:435–41.[CrossRef][Medline]
  39. Davies G, Salter J, Hills M, et al. Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 2003;9:2651–6.[Abstract/Free Full Text]
  40. Rahman MA, Dhar DK, Yamaguchi E, et al. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 2001;7:1325–32.[Abstract/Free Full Text]
  41. Fujiwaki R, Iida K, Kanasaki H, et al. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol 2002;33:213–9.[CrossRef][Medline]
  42. Lissbrant IF, Lissbrant E, Damber JE, Bergh A. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 2001;35:437–52.[CrossRef][Medline]
  43. Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 1997;75:1111–8.[Medline]
  44. Lim JT, Piazza GA, Han EK, et al. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol 1999;58:1097–107.[CrossRef][Medline]
  45. Liu XH, Kirschenbaum A, Yao S, et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000;164:820–5.[CrossRef][Medline]
  46. Roberts RO, Jacobson DJ, Girman CJ, et al. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002;77:219–25.[Medline]
  47. Perron L, Bairati I, Moore L, Meyer F. Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 2003;106:409–15.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
M. Mimeault, P. P. Mehta, R. Hauke, and S. K. Batra
Functions of Normal and Malignant Prostatic Stem/Progenitor Cells in Tissue Regeneration and Cancer Progression and Novel Targeting Therapies
Endocr. Rev., April 1, 2008; 29(2): 234 - 252.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Mehar, P. Macanas-Pirard, A. Mizokami, Y. Takahashi, G. E. N. Kass, and H. M. Coley
The Effects of Cyclooxygenase-2 Expression in Prostate Cancer Cells: Modulation of Response to Cytotoxic Agents
J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1181 - 1187.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Nie, Y. Guo, D. Yang, Y. Tang, Y. Chen, M.-T. Wang, A. Zacharek, Y. Qiao, M. Che, and K. V. Honn
Thromboxane A2 Receptors in Prostate Carcinoma: Expression and Its Role in Regulating Cell Motility via Small GTPase Rho
Cancer Res., January 1, 2008; 68(1): 115 - 121.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
X. Wang, J. K.L. Colby, P. Yang, S. M. Fischer, R. A. Newman, and R. D. Klein
The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue
Carcinogenesis, January 1, 2008; 29(1): 120 - 128.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
T. S. LEE, Y. T. JEON, J. W. KIM, J. K. WON, N. H. PARK, I. A. PARK, Y. S. JUHNN, S. B. KANG, H. P. LEE, and Y. S. SONG
Increased Cyclooxygenase-2 Expression Associated with Inflammatory Cellular Infiltration in Elderly Patients with Vulvar Cancer
Ann. N.Y. Acad. Sci., January 1, 2007; 1095(1): 143 - 153.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
J. A. Mitchell, R. Lucas, I. Vojnovic, K. Hasan, J. R. Pepper, and T. D. Warner
Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events
FASEB J, December 1, 2006; 20(14): 2468 - 2475.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Kobayashi, R. J. Barnard, S. M. Henning, D. Elashoff, S. T. Reddy, P. Cohen, P. Leung, J. Hong-Gonzalez, S. J. Freedland, J. Said, et al.
Effect of Altering Dietary {omega}-6/{omega}-3 Fatty Acid Ratios on Prostate Cancer Membrane Composition, Cyclooxygenase-2, and Prostaglandin E2
Clin. Cancer Res., August 1, 2006; 12(15): 4662 - 4670.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
H. Lu, W. Ouyang, and C. Huang
Inflammation, a Key Event in Cancer Development
Mol. Cancer Res., April 1, 2006; 4(4): 221 - 233.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, W.
Right arrow Articles by Damber, J.-E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, W.
Right arrow Articles by Damber, J.-E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online